Inclusion Criteria:

          1. Histologically or cytologically confirmed solid tumor or hematological malignancies

          2. Life expectancy ≥ 3 months

          3. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2

          4. Corrected QT interval (QTc) ≤ 450 ms in males, and ≤ 470 ms in females

          5. Adequate hematologic function

          6. International normalized ratio (INR), prothrombin time (PT) or activated partial
             thromboplastin time (aPTT) ≤1.5 x upper limit of normal (ULN)

          7. Adequate renal and liver function

          8. Willingness to use contraception

          9. Ability to understand and willingness to sign a written informed consent form

         10. Willingness and ability to comply with study procedures and follow-up examination

         11. Have provided tissue for biomarker analysis from a newly or recently-obtained biopsy
             of a tumor lesion not previously irradiated

        Exclusion Criteria:

          1. Received chemotherapy within 21 days (42 days for nitrosoureas or mitomycin C) prior
             to entering the study

          2. Received hormonal, biologic (< 2 half-lives), small molecule targeted therapies or
             other anti-cancer therapy within 21 days of study entry

          3. Radiation or surgery within 14 days of study entry, thoracic radiation within 28 days
             of study entry

          4. Has known active central nervous (CNS) metastases and/or carcinomatous meningitis.
             Patients who have received prior radiotherapy for previous brain metastasis must have
             discontinued steroids for 14 days prior to study entry and be clinically stable

          5. Continuance of toxicities due to prior radiotherapy or chemotherapy agents that do not
             recover to ≤ Grade 1 except alopecia

          6. Requirement for corticosteroid treatment, with the exception of megestrol, local use
             of steroid

          7. Use of therapeutic anticoagulants

          8. International normalized ratio (INR) or activated partial thromboplastin time (APTT) ≥
             1.5 x ULN

          9. Concurrent treatment with an investigational agent or device within 28 days prior to
             the first dose of therapy

         10. Unstable angina, myocardial infarction, or a coronary revascularization procedure
             within 180 days of study entry

         11. Neurologic instability per clinical evaluation due to tumor involvement of the central
             nervous system (CNS)

         12. History of Bell's palsy

         13. Active rheumatoid arthritis (RA), active inflammatory bowel disease, chronic
             infections, or any other disease or condition associated with chronic inflammation

         14. Active infection requiring systemic antibiotic/ antifungal medication

         15. Known or suspected Wilson's Disease

         16. Prior treatment with IAP inhibitors

         17. History of hypersensitivity to paclitaxel, or any therapeutic antibody

         18. Has an active autoimmune disease, or a documented history of autoimmune disease, or a
             syndrome that requires systemic steroids or immunosuppressive agents

         19. Is on chronic systemic steroid therapy

         20. Has received a live vaccine within 30 days prior to first dose

         21. Has had an allogeneic tissue/solid organ transplant, prior stem cell or bone marrow
             transplant